CONCLUSION

SCB shows high immediate technical performance and adequate short-term efficacy and safety.
SCB in native coronary arteries was associated with good angiographic outcome at 6-month follow-up

  • Principal Investigator
    Dr. Bernardo Cortese
    Unità Operativa di Cardiologia ASST Fatebenefratelli-Sacco, P.O. Fatebenefratelli Corso di Porta Nuova 23, Milano
STUDY DETAILS

• The aim of the study was to demonstrate the acute performance and the 6-month efficacy and safety of this device in a real world, complex population.
• All comer prospective registry of the first consecutive patients, who had at least one lesion treated with SCB between April and July 2016 at the first European centre.

STUDY ENDPOINTS

• The study endpoints encompassed major adverse cardiac events (MACE) at 1 year of clinical follow‐up and procedural success. MACE was defined as target lesion revascularization (TLR), target vessel myocardial infarction (TV‐MI) and cardiac death.
• Procedural success is defined as technical and angiographic success in the absence of a MACE at hospital discharge.

PATIENT, LESION AND PROCEDURE CHARACTERISTICS
CLINICAL AND ANGIOGRAPHIC OUTCOMES